Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $129,675.90 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Claire Mazumdar sold 6,905 shares of the business’s stock in a transaction dated Thursday, March 19th. The stock was sold at an average price of $18.78, for a total value of $129,675.90. Following the completion of the sale, the chief executive officer directly owned 339,392 shares of the company’s stock, valued at $6,373,781.76. This represents a 1.99% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Claire Mazumdar also recently made the following trade(s):

• On Wednesday, March 18th, Claire Mazumdar sold 6,499 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.84, for a total value of $122,441.16.
• On Friday, March 20th, Claire Mazumdar sold 1,596 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.95, for a total value of $30,244.20.
• On Monday, March 9th, Claire Mazumdar sold 36,766 shares of Bicara Therapeutics stock. The shares were sold at an average price of $19.17, for a total value of $704,804.22.
• On Friday, March 6th, Claire Mazumdar sold 3,817 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.75, for a total value of $71,568.75.
• On Wednesday, March 4th, Claire Mazumdar sold 2,631 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.73, for a total value of $49,278.63.
• On Thursday, March 5th, Claire Mazumdar sold 1,786 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.74, for a total value of $33,469.64.

Bicara Therapeutics Stock Down 2.0%

NASDAQ:BCAX opened at $18.41 on Monday. Bicara Therapeutics Inc. has a 12 month low of $7.80 and a 12 month high of $20.25. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -8.22 and a beta of -0.78. The company’s 50 day moving average is $16.98 and its 200-day moving average is $16.34.

Hedge Funds Weigh In On Bicara Therapeutics

Large investors have recently bought and sold shares of the stock. Vestal Point Capital LP grew its position in Bicara Therapeutics by 2.0% in the 3rd quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company’s stock worth $80,529,000 after purchasing an additional 100,000 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in shares of Bicara Therapeutics by 596.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company’s stock valued at $54,472,000 after buying an additional 2,771,868 shares during the period. Janus Henderson Group PLC bought a new stake in shares of Bicara Therapeutics in the fourth quarter valued at about $44,484,000. Vanguard Group Inc. grew its position in Bicara Therapeutics by 9.8% during the third quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company’s stock worth $34,753,000 after buying an additional 195,667 shares in the last quarter. Finally, State Street Corp grew its position in Bicara Therapeutics by 179.5% during the fourth quarter. State Street Corp now owns 1,649,537 shares of the company’s stock worth $27,762,000 after buying an additional 1,059,260 shares in the last quarter.

Analysts Set New Price Targets

Several brokerages recently commented on BCAX. Mizuho upgraded shares of Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. Citigroup assumed coverage on shares of Bicara Therapeutics in a report on Thursday, January 29th. They set an “outperform” rating for the company. UBS Group reiterated a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. BTIG Research reissued a “buy” rating on shares of Bicara Therapeutics in a research report on Thursday, January 15th. Finally, HC Wainwright restated a “buy” rating on shares of Bicara Therapeutics in a research note on Wednesday, January 14th. Six equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $30.25.

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.